Research units on pediatric psychopharmacology (RUPP) Autism Network: Background and rationale for an initial controlled study of risperidone

Child and Adolescent Psychiatric Clinics of North America

Volumn 9, Issue 1, 2000, Pages 201-224

  McDougle, C J ^a   Scahill, L ^a   McCracken, J T ^a   Aman, M G ^a   Tierney, E ^a   Arnold, L E ^a   Freeman, B J ^a   Martin, A ^a   McGough, J J ^a   Cronin, P ^a   Posey, D J ^a   Riddle, M A ^a   Ritz, L ^a   Swiezy, N B ^a   Vitiello, B ^a   Volkmar, F R ^a   Votolato, N A ^a   Walson, P ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HALOPERIDOL; NEUROLEPTIC AGENT; PIMOZIDE; RISPERIDONE; SEROTONIN;

ADOLESCENT; AUTISM; CHILD; CHILD PSYCHIATRY; DRUG CHOICE; DRUG EFFECT; DRUG USE; EXTRAPYRAMIDAL SYMPTOM; HUMAN; LONG TERM CARE; PRIORITY JOURNAL; PSYCHOPHARMACOLOGY; REVIEW;

EID: 0034101344     PISSN: 10564993     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1056-4993(18)30142-1     Document Type: Review

References (92)

1. Anderson G.M. Freedman D.X. Cohen D.J. Whole blood serotonin in autistic and normal subjects J Child Psychol Psychiatry 28 1987 885 900
2. Anderson G.M. Hoshino Y. Neurochemical studies of autism Cohen D.J. Volkmar F.R. Handbook of Autism and Pervasive Developmental Disorders ed 2 1997 John Wiley & Sons New York 325 343
3. Anderson L. Campbell M. The effects of haloperidol on discrimination learning and behavioral symptoms in autistic children J Autism Dev Disord 19 1989 227 239
4. Anderson L. Campbell M. Grega D. Haloperidol in the treatment of infantile autism: Effects on learning and behavioral symptoms Am J Psychiatry 141 1984 1195 1202
5. Arnold L.E., Aman M.G., Martin A., et al: Assessing autistic disorder in multisite randomized clinical trials (RCTs). J Autism Dev Disord, in press
6. Aman M.G. Singh N.N. Stewart A.W. The Aberrant Behavior Checklist: A behavior rating scale for the assessment of treatment effects Am J Ment Deficiency 5 1985 485 491
7. Baxter L.R. Phelps M.E. Mazziotta J.C. Local cerebral glucose metabolic rates in obsessive-compulsive disorder: A comparison with rates in unipolar depression and in normal controls Arch Gen Psychiatry 44 1987 211 218
8. Berent I. Carabeth J. Cordero M.M. Pancreatitis associated with risperidone treatment? Am J Psychiatry 154 1997 130 131
9. Bymaster F.P. Calligaro D.O. Falcone J.F. Radioreceptor binding profile of the atypical antipsychotic olanzapine Neuropsychopharmacology 14 1996 87 96
10. Campbell M. Adams P. Small A.M. Efficacy and safety of fenfluramine in autistic children J Am Acad Child Adolesc Psychiatry 27 1988 434 439
11. Campbell M. Anderson L. Meier M. A comparison of haloperidol and behavior therapy and their interaction in autistic children J Am Acad Child Adolesc Psychiatry 17 1978 640 655
12. Campbell M. Armenteros J.L. Malone R.P. Neuroleptic-related dyskinesias in autistic children: A prospective, longitudinal study J Am Acad Child Adolesc Psychiatry 36 1997 835 843
13. Casaer P. Walleghem D. Vandenbussche I. Pharmacokinetics and safety of risperidone in autistic children Pediatr Neurol 11 1994 89
14. Chouinard G. Jones B. Remington G. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients J Clin Psychopharmacol 13 1993 25 40
15. Ciaranello A.L. Ciaranello R.D. The neurobiology of infantile autism Ann Rev Neu-rosci 18 1995 101 128
16. Cohen I.L. Campbell M. Posner D. Behavioral effects of haloperidol in young autistic children J Am Acad Child Adolesc Psychiatry 19 1980 665 677
17. Connolly H.M. Crary J.L. McGoon M.D. Valvular heart disease associated with fenfluramine-phentermine N Engl J Med 337 1997 581 588
18. Cook E.H. Jr Perry B.D. Dawson G. Receptor inhibition by immunoglobulins: Specific inhibition by autistic children, their relatives, and control subjects J Autism Dev Disord 23 1993 67 78
19. Corbett R. Hartman H. Kerman L.L. Effects of atypical antipsychotic agents on social behavior in rodents Pharmacol Biochem Behav 45 1993 9 17
20. Cozza S.J. Edison D.L. Risperidone in adolescents J Am Acad Child Adolesc Psychiatry 33 1994 1211
21. Czobor P. Volavka J. Meibach R.C. Effect of risperidone on hostility in schizophrenia J Clin Psychopharmacol 15 1995 243 249
22. Demb H. Risperidone. Maybe this shouldn’t be the last resort Antanitus D. Success Stories in Developmental Disabilities vol 4 1995 Liberty Healthcare Corporation Waltham, MA 11 14
23. Demb H. Risperidone in young children with pervasive developmental disorders and other developmental disabilities J Child Adolesc Psychopharmacol 6 1996 79 80
24. Edleman R.J. Risperidone side effects J Am Acad Child Adolesc Psychiatry 35 1996 4 5
25. Ekman G. Miranda-Linné F. Gillberg C. Fenfluramine treatment of twenty children with autism J Autism Dev Disord 19 1989 511 532
26. Feeney D.J. Klykylo W. Risperidone and tardive dyskinesia J Am Acad Child Adolesc Psychiatry 35 1996 1421 1422
27. Findling R.L. Maxwell K. Wiznitzer M. An open clinical trial of risperidone monotherapy in young children with autistic disorder Psychopharmacol Bull 33 1997 155 159
28. Fisman S. Steele M. Use of risperidone in pervasive developmental disorders: A case series J Child Adolesc Psychopharmacol 6 1996 177 190
29. Fisman S. Steele M. Short J. Case study: Anorexia nervosa and autistic disorder in an adolescent girl J Am Acad Child Adolesc Psychiatry 35 1996 937 940
30. Freeman B.J. Ritvo E.R. Yokota A. A scale for rating symptoms of patients with the syndrome of autism in real-life settings J Am Acad Child Psychiatry 25 1986 130 136
31. Frischauf E. Drug therapy in autism J Am Acad Child Adolesc Psychiatry 36 1997 577
32. Geller E. Ritvo E. Freeman B. Preliminary observations on the effect of fenfluramine on blood serotonin and symptoms in three autistic boys N Engl J Med 307 1982 165 169
33. Gillberg C. Svennerholm L. Hamilton-Hellberg C: Childhood psychosis and monoamine metabolites in spinal fluid J Autism Dev Disord 13 1983 383 396
34. Gordon C.T. Rapoport J.L. Hamburger S.D. Differential response of seven subjects with autistic disorder to clomipramine and desipramine Am J Psychiatry 149 1992 363 366
35. Gordon C.T. State R.C. Nelson J.E. A double-blind comparison of clomipramine, desipramine, and placebo in the treatment of autistic disorder Arch Gen Psychiatry 50 1993 441 447
36. Goyette C.H. Conners C.K. Ulrich R.F. Normative data on revised Conners parent and teacher rating scales J Abnorm Child Psychol 6 1978 221 236
37. Guy W. ECDEU assessment manual for psychopharmacology (NIMH Publication No. 76-338) 1976 U.S. DHEW, NIMH Washington, DC
38. Hardan A. Johnson K. Johnson C. Risperidone treatment of children and adolescents with developmental disorders J Am Acad Child Adolesc Psychiatry 35 1996 1551 1556
39. Heimann S.W. High-dose olanzapine in an adolescent J Am Acad Child Adolesc Psychiatry 38 1999 496
40. Hertel P. Nomikos G.G. Schiistrom B. Risperidone dose-dependently increases extracellular concentrations of serotonin in the rat frontal cortex: Role of alpha-2-adrenoceptor antagonism Neuropsychopharmacology 17 1997 44 55
41. Heuring R.E. Peroutka S.J. Characterization of a novel 3H-5-hydroxytryptamine binding site subtype in bovine brain membranes J Neurosci 7 1987 894 903
42. Horrigan J.P. Barnhill L.J. Risperidone and explosive aggressive autism J Autism Dev Disord 27 1997 313 323
43. Horrigan J.P. Barnhill L.J. Courvoisie H.E. Olanzapine in PDD J Am Acad Child Adolesc Psychiatry 36 1997 1166 1167
44. Hoshino Y. Tachibana J.R. Watanabe M. Serotonin metabolism and hypothalamic-pituitary function in children with infantile autism and minimal brain dysfunction Jpn J Psychiatry Neurol 26 1984 937 945
45. Jeanblanc W. Davis Y.B. Risperidone for treating dementia-associated aggression Am J Psychiatry 152 1995 1239
46. Kane J. Honigfeld G. Singer J. Clozapine for the treatment-resistant schizophrenic: A double-blind comparison with chlorpromazine Arch Gen Psychiatry 45 1988 789 796
47. Kay S.R. Opler L.A. Lindenmayer J.P. Reliability and validity of the positive and negative symptom scale for schizophrenia Psychiatry Res 23 1987 99 110
48. Kumra S. Herion D. Jacobsen L.K. Case study: Risperidone-induced hepatotoxic-ity in pediatric patients J Am Acad Child Adolesc Psychiatry 35 1997 701 705
49. Landau J. Martin A. Is liver function monitoring warranted during risperidone treatment? J Am Acad Child Adolesc Psychiatry 37 1998 1007 1008
50. Ley sen J.E. Gommeren W. Eens A. Biochemical profile of risperidone, a new antipsychotic J Pharmacol Exp Ther 247 1988 661 670
51. Lombroso P.J. Scahill L. King R.A. Risperidone treatment of children and adolescents with chronic tic disorders: A preliminary report J Am Acad Child Adolesc Psychiatry 34 1995 1147 1152
52. Lott R.S. Kerrick J.M. Cohen S.A. Clinical and economic aspects of risperidone treatment in adults with mental retardation and behavioral disturbance Psychopharmacol Bull 32 1994 721 729
53. Mandoki M.W. Risperidone treatment of children and adolescents: Increased risk of extrapyramidal side effects? J Child Adolesc Psychopharmacol 5 1995 49 67
54. Martin A. Keonig K. Scahill L. Open-label quetiapine in the treatment of children and adolescents with autistic disorder J Child Adolesc Psychopharmacol 9 1999 99 107
55. McBride P.A. Anderson G.M. Hertzig M.E. Effects of diagnosis, race, and puberty on platelet serotonin levels in autism and mental retardation J Am Acad Child Adolesc Psychiatry 37 1998 767 776
56. McBride P.A. Anderson G.M. Hertzig M.E. Serotonergic responsivity in male young adults with autistic disorder: Results of a pilot study Arch Gen Psychiatry 46 1989 213 221
57. McDougle C.J. Psychopharmacology Cohen D.J. Volkmar F.R. Handbook of Autism and Pervasive Developmental Disorders ed 2 1997 John Wiley & Sons New York 707 729
58. McDougle C.J. Brodkin E.S. Yeung P.P. Risperidone in adults with autism or pervasive developmental disorder J Child Adolesc Psychopharmacol 5 1995 273 282
59. McDougle C.J. Epperson C.N. Price L.H. Obsessive-compulsive symptoms with neuroleptics J Am Acad Child Adolesc Psychiatry 35 1996 837
60. McDougle C.J. Fleischmann R.L. Epperson C.N. Risperidone addition in fluvox-amine-refractory obsessive compulsive disorder: Three cases J Clin Psychiatry 56 1995 526 528
61. McDougle C.J. Holmes J.P. Bronson M.R. Risperidone treatment of children and adolescents with pervasive developmental disorders A prospective open-label study J Am Acad Child Adolesc Psychiatry 36 1997 685 693
62. McDougle C.J. Holmes J.P. Carlson D.C. A double-blind, placebo-controlled study of risperidone in adults with autistic disorder and other pervasive developmental disorders Arch Gen Psychiatry 55 1998 633 641
63. McDougle C.J. Kresch L.E. Goodman W.K. A case-controlled study of repetitive thoughts and behavior in adults with autistic disorder and obsessive-compulsive disorder Am J Psychiatry 152 1995 722 777
64. McDougle C.J. Naylor S.T. Cohen D.J. A double-blind, placebo-controlled study of fluvoxamine in adults with autistic disorder Arch Gen Psychiatry 53 1996 1001 1008
65. McDougle C.J. Naylor S.T. Cohen D.J. Effects of tryptophan depletion in drug-free adults with autistic disorder Arch Gen Psychiatry 53 1996 993 1000
66. McDougle C.J. Price L.H. Volkmar F.R. Recent advances in the pharmacotherapy of autism and related conditions Child Adolesc Psych Clin N Am 3 1994 71 89
67. Moller H.J. Pelzer E. Kissling W. Efficacy and tolerability of a new antipsychotic compound (risperidone) Results of a pilot study Pharmacopsychiatry 24 1991 185 189
68. Naruse H. Nagahata M. Nakane Y. A multi-center double-blind trial of pimozide (Orap), haloperidol and placebo in children with behavior disorders, using cross-over design Acta Paedopsychiatrica 48 1982 173 184
69. Nicholson R. Awad G. Sloman L. An open trial of risperidone in young autistic children J Am Acad Child Adolesc Psychiatry 37 1998 372 376
70. Perry R. Campbell M. Adams P. Long-term efficacy of haloperidol in autistic children: Continuous versus discontinuous drug administration J Am Acad Child Adolesc Psychiatry 28 1989 87 92
71. Perry R. Pataki C. Munoz-Silva D.M. Risperidone in children and adolescents with pervasive developmental disorder: Pilot trial and follow-up J Child Adolesc Psychopharmacol 7 1997 167 179
72. Posey D.J., Walsh K.H., Wilson G.A., et al: Risperidone in the treatment of two very young children with autism. J Child Adolesc Psychopharmacol, in press
73. Potenza M.N. Holmes J.P. Kanes S.J. Olanzapine treatment of children, adolescents, and adults with pervasive developmental disorders: An open-label pilot study J Clin Psychopharmacol 19 1999 37 44
74. Potenza M.N. McDougle C.J. Potential of atypical antipsychotics in the treatment of nonpsychotic disorders CNS Drugs 9 1998 213 232
75. Purdon S.E. Lit W. Labelle A. Risperidone in the treatment of pervasive developmental disorder Can J Psychiatry 39 1994 400 405
76. Quintana H. Keshavan M. Case study: Risperidone in children and adolescents with schizophrenia J Am Acad Child Adolesc Psychiatry 34 1995 1292 1296
77. Ravin D.S. Levenson J.W. Fatal cardiac event following initiation of risperidone therapy Ann Pharmacother 31 1997 867 870
78. Ritvo E.R. Freeman B.J. Geller E. Effects of fenfluramine on 14 outpatients with the syndrome of autism J Am Acad Child Adolesc Psychiatry 22 1983 549 558
79. Ritvo E.R. Freeman B.J. Yuwiler A. Fenfluramine treatment of autism: UCLA collaborative study of 81 patients at nine medical centers Psychopharmacol Bull 22 1986 133 140
80. Rowan A.B. Malone R.P. Tics with risperidone withdrawal J Am Acad Child Adolesc Psychiatry 36 1997 162 163
81. Rubin M. Use of atypical antipsychotics in children with mental retardation, autism, and other developmental disabilities Psychiatr Ann 27 1997 219 221
82. Scahill L., McCracken J.T., McDougle C.J., et al: The design and methodology of a double-blind placebo-controlled investigation of risperidone in children and adolescents with autistic disorder. J Child Adolesc Psychopharmacol, in press 224 McDOUGLE et al
83. Schain R.J. Freedman D.X. Studies on 5-hydroxyindole metabolism in autistic and other mentally retarded children J Pediatrics 58 1961 315 320
84. Schuster C. Lewis M. Seiden L. Fenfluramine: Neurotoxicity Psychopharmacol Bull 22 1986 148 151
85. Schwam J.S. Klass E. Alonso C. Risperidone and refusal to eat J Am Acad Child Adolesc Psychiatry 37 1998 572 573
86. Simeon J.G. Carrey N.J. Wiggins D.M. Risperidone effects in treatment-resistant adolescents: Preliminary case reports J Child Adolesc Psychopharmacol 5 1995 69 79
87. Todd R.D. Ciaranello R.D. Demonstration of inter- and intraspecies differences in serotonin binding sites by antibodies from an autistic child Proc Natl Acad Sci USA 82 1985 612 616
88. Tran P.V. Hamilton S.H. Kuntz A.J. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders J Clin Psychopharmacol 17 1997 407 418
89. Vanden Borre R. Vermote R. Buttiëns M. Risperidone as add-on therapy in behavioural disturbances in mental retardation: A double-blind placebo-controlled cross-over study Acta Psychiatr Scand 87 1993 167 171
90. Woerner M.G. Sheitman B.B. Lieberman J.A. Tardive dyskinesia induced by risperidone? Am J Psychiatry 153 1996 843
91. Yuwiler A. Shih J.C. Chen C.H. Hyperserotoninemia and antiserotonin antibodies in autism and other disorders J Autism Dev Disord 22 1992 33 45
92. Zuddas A. Ledda M.G. Fratta A. Clinical effects of clozapine on autistic disorder Am J Psychiatry 153 1996 738